IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+8.51%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(+33%)
Cap. Flow
+$321M
Cap. Flow
% of AUM
28.43%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
99
New
35
Increased
28
Reduced
13
Closed
17
Top Buys
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Vera Therapeutics
VERA
|
$27.5M |
| 4 |
CVS Health
CVS
|
$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
$21.8M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$35M |
| 2 |
Novartis
NVS
|
$23M |
| 3 |
Tenet Healthcare
THC
|
$16.4M |
| 4 |
Arcellx
ACLX
|
$13.4M |
| 5 |
Medtronic
MDT
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Crinetics Pharmaceuticals
CRNX
$3.26B
| $15.3M | 1.31% |
300,000
| – | – |
|
27
AstraZeneca
AZN
$255B
| $14.7M | 1.26% |
+225,000
| New | +$14.7M |
|
28
Edgewise Therapeutics
EWTX
$1.54B
| $14.7M | 1.25% |
+550,000
| New | +$14.7M |
|
29
Jasper Therapeutics
JSPR
$44.2M
| $13.9M | 1.18% |
650,000
+300,000
| +86% | +$6.41M |
|
30
Fresenius Medical Care
FMS
$14.3B
| $13.6M | 1.16% |
600,000
+150,000
| +33% | +$3.4M |
|
31
Apellis Pharmaceuticals
APLS
$3.51B
| $13.4M | 1.14% |
+420,000
| New | +$13.4M |
|
|
32
Medtronic
MDT
$118B
| $12M | 1.02% |
150,000
-150,000
| -50% | -$12M |
|
33
Acadia Healthcare
ACHC
$2.15B
| $11.9M | 1.01% |
+300,000
| New | +$11.9M |
|
34
DexCom
DXCM
$30.9B
| $11.7M | 0.99% |
150,000
+30,000
| +25% | +$2.33M |
|
35
BioNTech
BNTX
$24.1B
| $11.4M | 0.97% |
100,000
+50,000
| +100% | +$5.7M |
|
36
Waters Corp
WAT
$17.3B
| $11.1M | 0.95% |
+30,000
| New | +$11.1M |
|
37
Teva Pharmaceuticals
TEVA
$21.5B
| $11M | 0.94% |
+500,000
| New | +$11M |
|
38
MoonLake Immunotherapeutics
MLTX
$3.78B
| $10.8M | 0.92% |
200,000
-20,000
| -9% | -$1.08M |
|
39
Mineralys Therapeutics
MLYS
$1.94B
| $10.8M | 0.92% |
875,000
+519,000
| +146% | +$6.39M |
|
40
Janux Therapeutics
JANX
$1.38B
| $10.7M | 0.91% |
+200,000
| New | +$10.7M |
|
41
Alnylam Pharmaceuticals
ALNY
$58.6B
| $10.6M | 0.9% |
45,000
+20,000
| +80% | +$4.71M |
|
42
Humana
HUM
$37.5B
| $10.1M | 0.87% |
+40,000
| New | +$10.1M |
|
43
Oscar Health
OSCR
$4.57B
| $9.41M | 0.8% |
+700,000
| New | +$9.41M |
|
44
Cooper Companies
COO
$13.3B
| $9.19M | 0.78% |
100,000
-10,000
| -9% | -$919K |
|
45
Krystal Biotech
KRYS
$4.35B
| $8.62M | 0.73% |
+55,000
| New | +$8.62M |
|
46
Exact Sciences
EXAS
$9.33B
| $8.43M | 0.72% |
150,000
+70,000
| +88% | +$3.93M |
|
47
Rhythm Pharmaceuticals
RYTM
$6.75B
| $8.4M | 0.72% |
+150,000
| New | +$8.4M |
|
48
89bio
ETNB
$1.37B
| $7.82M | 0.67% |
1,000,000
+500,000
| +100% | +$3.91M |
|
|
49
Arcellx
ACLX
$3.95B
| $7.67M | 0.65% |
100,000
-175,000
| -64% | -$13.4M |
|
50
Protara Therapeutics
TARA
$125M
| $7.39M | 0.63% |
+1,400,000
| New | +$7.39M |
|